. Author manuscript; available in PMC: 2014 Feb 13.

Published in final edited form as: Cancer Biol Ther. 2008 Dec 7;7(12):1938–1946. doi: 10.4161/cbt.7.12.6942

Table 1. CI-1033 selectively decreases the proportion of ST88-14 NF1 MPNST cells in the S-phase of the cell cycle.

ST88-14 and STS-26T MPNST cells were treated as indicated with a range of CI-1033 concentrations that dose-dependently inhibit proliferation of NF1 MPNST cells (Fig. 5). The cells were processed for analysis of cell cycle distribution by flow cytometry.

Treatment: [CI-1033] for 48 h	ST88-14			STS-26T
	% of cells in:			% of cells in:
	G₁	S	G₂/M	G₁	S	G₂/M
0	63	28	9	70	21	9
100 nM	66	25	9	70	21	9
250 nM	70	22	8	70	21	9
1000 nM	80	16	4	66	24	10